Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 2:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 55 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: NAD Clear all
Completed Phase 1Phase 2 Interventional

Sirtuin-NAD Activator in Alzheimer's Disease

NCT05040321
View directory record Official record
Conditions
Alzheimer's Disease (Incl Subtypes), Dementia
Interventions
MIB-626, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
55 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 3, 2026, 2:29 AM EDT
Completed Not applicable Interventional Results available

NAD+ and Exercise in FA

NCT04192136
View directory record Official record
Conditions
Friedreich Ataxia 1
Interventions
Nicotinamide Riboside, Placebo, Exercise Intervention
Dietary Supplement · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 40 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 3, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease

NCT03815916
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Gold Nanocrystals
Drug
Lead sponsor
Clene Nanomedicine
Industry
Eligibility
30 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 3, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis

NCT03865927
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Placebo Oral Tablet, GKT137831
Other · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • New Orleans, Louisiana • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 3, 2026, 2:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Use of 31P MRS to Assess Brain NAD+ in Healthy Current and Former Collegiate Athletes

NCT02721537
View directory record Official record
Conditions
Concussion, Mild
Interventions
Nicotinamide Riboside, Matching placebo
Dietary Supplement · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
2
States / cities
Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Sep 3, 2026, 2:29 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus

NCT06032923
View directory record Official record
Conditions
Systemic Lupus Erythematosus (Sle)
Interventions
Nicotinamide Riboside
Dietary Supplement
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 120 Years · Female only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 3, 2026, 2:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Nicotinamide Adenine Dinucleotide (NAD) on Brain Function and Cognition

NCT02942888
View directory record Official record
Conditions
Mild Cognitive Impairment, NAD
Interventions
Nicotinamide riboside, Sugar Pill
Dietary Supplement
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
65 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Sep 3, 2026, 2:29 AM EDT
Not yet recruiting Phase 1 Interventional

NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome

NCT07278492
View directory record Official record
Conditions
Down Syndrome (DS)
Interventions
MIB-626, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 3, 2026, 2:29 AM EDT
Withdrawn Phase 2 Interventional

31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis (REPAIR-ALS)

NCT03843710
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Gold Nanocrystals
Drug
Lead sponsor
Clene Nanomedicine
Industry
Eligibility
35 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2023 · Synced Sep 3, 2026, 2:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Measurement of NAD+ Synthesis in Human Skeletal Muscle

NCT04905446
View directory record Official record
Conditions
Skeletal Muscle
Interventions
Deuterated nicotinamide (D4-NAM) IV infusion, Skeletal muscle biopsy, Skin tissue biopsy
Other · Procedure
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
21 Years to 40 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Sep 3, 2026, 2:29 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Biomarker Study to Evaluate Correlations Between Epigenetic Aging and NAD+ Levels in Healthy Volunteers

NCT04220658
View directory record Official record
Conditions
Epigenetics
Interventions
Biomarker study
Other
Lead sponsor
Elysium Health
Industry
Eligibility
25 Years to 80 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Sep 3, 2026, 2:29 AM EDT
Completed Phase 2 Interventional

Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome

NCT04604704
View directory record Official record
Conditions
Covid19, Long COVID-19, Post-COVID-19 Syndrome
Interventions
Naltrexone, NAD+
Drug · Dietary Supplement
Lead sponsor
AgelessRx
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 24, 2023 · Synced Sep 3, 2026, 2:29 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults

NCT07144527
View directory record Official record
Conditions
Aging, Frailty, Exercise Tolerance, Healthy Male and Female Subjects
Interventions
NMN, betaine, low-dose hydrogen peroxide (EGA), Nicotinamide Mononucleotide (NMN), Placebo
Dietary Supplement
Lead sponsor
Scott Silveira
Other
Eligibility
60 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 3, 2026, 2:29 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression

NCT06866236
View directory record Official record
Conditions
Chronic Kidney Diseases, Acute Kidney Injury, Kidney Failure
Interventions
QRX-3
Drug
Lead sponsor
Ebima Clifford Okundaye
Industry
Eligibility
18 Years to 90 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pasedena, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Sep 3, 2026, 2:29 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Impacts of Nicotinamide Riboside on Functional Capacity and Muscle Physiology in Older Veterans

NCT04691986
View directory record Official record
Conditions
Sarcopenia, Nicotinamide Adenine Dinucleotide Concentration, Muscle Quality and NAD+ Content
Interventions
Nicotinamide Riboside, Placebo
Dietary Supplement · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years to 85 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 3, 2026, 2:29 AM EDT
Completed Phase 4 Interventional Results available

Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19

NCT04809974
View directory record Official record
Conditions
Covid19, Sequelae of; Infection, Cognitive Symptom
Interventions
Niagen
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 3, 2026, 2:29 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Tracing the Metabolic Flux of Orally Administered NAD+ Precursors

NCT06882096
View directory record Official record
Conditions
Healthy Adults
Interventions
Nicotinamide Mononucleotide (NMN), Nicotinamide (NAM)
Drug
Lead sponsor
Metro International Biotech, LLC
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Sep 3, 2026, 2:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Nicotinamide Riboside in Systolic Heart Failure

NCT03423342
View directory record Official record
Conditions
Heart Failure, Systolic
Interventions
nicotinamide riboside, Placebo
Dietary Supplement · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Sep 3, 2026, 2:29 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Nicotinamide Riboside, Vit B3 Analogue, and Brain Energy Metabolism

NCT07649161
View directory record Official record
Conditions
Healthy Adult
Interventions
Niagen®
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 3, 2026, 2:29 AM EDT
Recruiting Phase 2 Interventional

NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial

NCT04750616
View directory record Official record
Conditions
Ischemia Reperfusion Injury, Myocardial Injury, Acute Kidney Injury
Interventions
Niacinamide, Placebo
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Sep 3, 2026, 2:29 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

IV Administration of ChromaDex's Niagen® as Compared to NAD+

NCT06382688
View directory record Official record
Conditions
Healthy Aging
Interventions
NAD+ (nicotinamide adenine dinucleotide) IV, Niagen® (nicotinamide riboside) IV, Niagen® (nicotinamide riboside) oral, Placebo
Dietary Supplement · Other
Lead sponsor
Nutraceuticals Research Institute
Other
Eligibility
40 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Franklin, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 3, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

NAD+ Precursor Supplementation in Friedreich's Ataxia

NCT04817111
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
MIB-626
Drug
Lead sponsor
Metro International Biotech, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2023 · Synced Sep 3, 2026, 2:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment

NCT03482167
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Niagen®, Placebo
Drug · Other
Lead sponsor
University of Delaware
Other
Eligibility
60 Years to 90 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 3, 2026, 2:29 AM EDT
Completed Phase 2 Interventional

Phase 2a MIB-626 vs. Placebo COVID-19

NCT05038488
View directory record Official record
Conditions
Covid19, Stage 1 Acute Kidney Injury
Interventions
MIB-626, Placebo, Home Treatment
Drug · Other
Lead sponsor
Metro International Biotech, LLC
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Sep 3, 2026, 2:29 AM EDT